

# 1 Delayed booster dosing improves 2 human antigen-specific Ig and B cell 3 responses to the RH5.1/AS01<sub>B</sub> 4 malaria vaccine

5  
6 **CM Nielsen**<sup>1</sup>, JR Barrett<sup>1</sup>, C Davis<sup>2</sup>, JK Fallon<sup>3</sup>, C Goh<sup>1</sup>, AR Michell<sup>3,4</sup>, C Griffin<sup>2</sup>, A Kwok<sup>1,5</sup>, C  
7 Loos<sup>2,3</sup>, S Darko<sup>6</sup>, F Laboune<sup>6</sup>, SE Silk<sup>1</sup>, M Tekman<sup>7</sup>, JR Francica<sup>6,8</sup>, A Ransier<sup>6</sup>, RO Payne<sup>1,9</sup>,  
8 AM Minassian<sup>1</sup>, DA Lauffenburger<sup>2</sup>, RA Seder<sup>6</sup>, DC Douek<sup>6</sup>, G Alter<sup>3</sup>, SJ Draper<sup>1</sup>

9  
10 <sup>1</sup> University of Oxford, Oxford, United Kingdom.

11 <sup>2</sup> Department of Biological Engineering, MIT, Cambridge, USA.

12 <sup>3</sup> Ragon Institute of MGH, MIT and Harvard, Boston, USA.

13 <sup>4</sup> Present affiliation: University of Illinois at Chicago, Chicago, USA.

14 <sup>5</sup> Wellcome Center for Human Genetics, University of Oxford, Oxford, United Kingdom.

15 <sup>6</sup> Vaccine Research Center, NIAID/NIH, Bethesda, USA.

16 <sup>7</sup> Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine,  
17 University of Freiburg, Freiburg, Germany

18 <sup>8</sup> Present affiliation: AstraZeneca, Washington DC, USA.

19 <sup>9</sup> Present affiliation: Department of Infection, Immunity and Cardiovascular Disease, University  
20 of Sheffield, Sheffield, UK

21

## 22 Abstract

23

24 **Background:** Antibodies are crucial for vaccine-mediated protection against many pathogens.

25 Modifications to vaccine delivery that increase antibody magnitude, longevity, and/or quality

26 are therefore of great interest for maximising efficacy. We have previously shown that a

27 delayed fractional (DFx) dosing schedule (0-1-6mo) – using AS01<sub>B</sub>-adjuvanted RH5.1 malaria

28 antigen – substantially improves serum IgG durability as compared to monthly dosing (0-1-

29 2mo; NCT02927145). However, the underlying mechanism and whether there are wider

30 immunological changes with DFx dosing was unclear.

31

32 **Methods:** Immunokinetics of PfRH5-specific Ig across multiple isotypes were compared

33 between DFx and monthly regimen vaccinees. Peak responses were characterised in-depth

34 with a systems serology platform including biophysical and functional profiling. Computational

35 modelling was used to define the humoral feature set associated with DFx dosing. PfRH5-

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 specific B cells were quantified by flow cytometry and sorted for single cell RNA sequencing  
37 (scRNA-seq). Differential gene expression between DFx and monthly dosing regimens was  
38 explored with Seurat, DESeq2 and gene set enrichment analysis.

39

40 Results: DFx dosing increases the frequency of circulating PfRH5-specific B cells and  
41 longevity of PfRH5-specific IgG1, as well as other isotypes and subclasses. At the peak  
42 antibody response, DFx dosing was distinguished by a systems serology feature set  
43 comprising increased FcRn-binding, IgG avidity, and proportion of G2B and G2S2F IgG Fc  
44 glycans, alongside decreased IgG3, antibody-dependent complement deposition, and  
45 proportion of G1S1F IgG Fc glycan. At the same time point, scRNA-seq of PfRH5-specific B  
46 cells revealed enriched plasma cell and Ig / protein export signals in the monthly dosing group  
47 as compared to DFx vaccinees.

48

49 Conclusions: DFx dosing of the RH5.1/AS01<sub>B</sub> vaccine had a profound impact on the humoral  
50 response. Our data suggest plausible mechanisms relating to improved FcRn-binding (known  
51 to improve Ig longevity) and a potential shift from short-lived to long-lived plasma cells. Recent  
52 reports of the positive impact of delayed boosting on SARS-CoV-2 vaccine immunogenicity  
53 highlight the broad relevance of these data.

## 54 Introduction

55 Vaccines are among public health's most effective tools for combatting infectious disease but  
56 a poor understanding of the underlying immunological mechanisms frequently impedes  
57 vaccine development. One of the greatest perennial issues for the vaccinology field is a lack  
58 of knowledge of how to induce more *durable* immune responses in the target populations.  
59 While many vaccine candidates generate encouraging peak antibody concentrations, these  
60 often wane rapidly in the following months. This rapid decay can be highly problematic and  
61 poses a particular issue for pathogens such as blood-stage malaria where the threshold  
62 antibody concentration required for protection is high (1, 2).

63

64 Interestingly, in a clinical trial with the leading blood-stage malaria vaccine candidate (RH5.1/  
65 AS01<sub>B</sub>) we have recently shown that a delayed fractional booster 0-1-6-month schedule  
66 (“DFx”) induces higher magnitude vaccine-specific antibody as compared to a more typically  
67 used 0-1-2-month “monthly” vaccination schedule (NCT02927145). Moreover, the DFx anti-  
68 PfRH5 serum IgG plateaus at a 10X higher concentration over the next 2 years – an  
69 unprecedented finding (1). While data from other malaria vaccine trials – and more recent  
70 SARS-CoV-2 trials (3-5) – are broadly supportive of a beneficial impact of delayed (fractional)  
71 booster dosing on antibody-mediated immunity, there is yet to be any other demonstration of  
72 a comparable impact of vaccine regimen on human antibody longevity or any analyses  
73 involving the direct detection and isolation of antigen-specific B cells (6-9).

74

75 Here, using samples from the RH5.1/AS01<sub>B</sub> trial, we interrogate the PfRH5-specific antibody  
76 and B cell responses in both DFx and monthly regimens (**Table 1**). Through a combination of  
77 immunokinetic, systems serology, and single cell RNA sequencing (scRNA-seq) analyses, we  
78 identify features of the PfRH5-specific Ig and B cell responses that discriminate between these  
79 dosing regimens. These data are informative for understanding the potential underlying  
80 mechanisms of DFx-mediated improvements in humoral immunity, and will be of great

81 relevance for efforts to further optimise durable antibody responses against malaria and other  
82 diseases where vaccine-induced protection is antibody-mediated. This work builds on  
83 previously published data demonstrating improved PfRH5-specific IgG and Tfh2  
84 immunogenicity following PfRH5 delivery by RH5.1/AS01<sub>B</sub> as compared to a heterologous  
85 viral vector platform (NCT02181088) (1, 10, 11).

Type of booster dosing regimen	VAC063 trial group	Vaccination time point and RH5.1 dose (all vaccinations co-administered with AS01 <sub>B</sub> adjuvant)				Vaccinee Demographics	
		Day 0	Day 28	Day 56	Day 182	% female	Median age, years (range)
Monthly	1 'Monthly-low'	2µg	2µg	2µg		65 (22/34)	31 (18-46)
	2 'Monthly-medium'	10µg	10µg	10µg			
	4 'Monthly-high'	50µg	50µg	50µg			
Delayed fractional	3 'DFx'	50µg	50µg		10µg	67 (8/12)	28 (25-42)

86  
87

88 **Table 1. Overview of vaccination regimen.**

89 PfRH5.1 = full-length PfRH5 protein (1, 12). Vaccinee demographics relate only to those included in this study.

## 90 Results

### 91 Delayed fractional (DFx) dosing improves longevity of circulating PfRH5- 92 specific B cells and IgG1

93 Using PfRH5 probes to detect circulating PfRH5-specific memory IgG+ B cells (defined as live  
94 CD19+CD21+CD27+IgG+probe++ single lymphocytes; **Supplemental Figure 1A**), we first  
95 established that protein/AS01<sub>B</sub> vaccinees had higher frequencies of these antigen-specific  
96 cells in circulation at both 4-weeks and 12-weeks after final vaccination as compared to  
97 heterologous viral vector vaccinees (**Figure 1A**). Within the protein/AS01<sub>B</sub> trial, vaccinees  
98 receiving a DFx regimen (**Table 1**) – rather than the monthly dosing regimen – showed higher  
99 responses 2-, 4-, and 12-weeks after the final vaccination (**Figure 1B**). The discrepancy was  
100 even more pronounced if PfRH5-specific cells were defined less conservatively with only one  
101 probe: significant differences were sustained out to 12-weeks following final vaccination  
102 (PfRH5-PE; **Supplemental Figure 1B,C**). While the source of circulating anti-PfRH5 serum  
103 IgG is presumably bone marrow resident long-lived plasma cells (LLPCs) rather than  
104 circulating anti-PfRH5 memory B cells (mBCs), these two parameters do correlate at 4-weeks  
105 after the final vaccination suggesting a more robust B cell response with the DFx regimen as  
106 compared to monthly regimen across multiple germinal centre B cell fate lineages (**Figure**  
107 **1C**). PfRH5-specific memory IgM+ responses were detectable but minimal (**Supplemental**  
108 **Figure 1D**). These results are also consistent with reports from similar “Fx017M” dosing (0-1-  
109 7mo) with the PfCSP-based pre-erythrocytic malaria vaccine RTS,S. In this instance, PfCSP-  
110 specific mBCs were indirectly detected at higher frequencies in Fx017M vaccinees as  
111 compared to the monthly 0-1-2mo regimen following 5-day PfCSP stimulation (9).

112


113 To delve further into the differences in anti-PfRH5 Ig immunokinetics between DFx and  
114 monthly vaccinees, we developed standardised ELISAs for anti-PfRH5 IgG1-4, IgA, IgA1-2,  
115 and IgM to assay sera samples from key post-vaccination time points (**Figure 1D-G**;  
116 **Supplemental Figure 2A-D**). Although there was no significant difference at the peak time

117 points (2- or 4-weeks following final vaccination), 6-months after the final vaccination the  
118 median IgG1 AU was 4130 for DFx vaccinees as compared to 628AU in the monthly regimen  
119 vaccinees, i.e.  $\approx 5$ -fold increase ( $p < 0.0001$ ; Mann Whitney test). After  $> 1.5$  years, the IgG1  
120 median AU values were 1984 and 133, respectively, i.e.  $\approx 15$ -fold difference ( $p < 0.0001$ ; Mann  
121 Whitney test). In the absence of such stark differences in IgG2 (**Figure 1E**), IgG3 (**Figure 1F**)  
122 and IgG4 (**Figure 1G**), these data suggest that the majority of the improvement in longevity  
123 observed in the total anti-PfRH5-specific IgG response (10) is attributable to the IgG1  
124 component. In fact, while levels of anti-PfRH5 IgG3 are not significantly different at 6-months  
125 or 1.5-years after the final vaccination (**Figure 1F**), both IgG2 and IgG4 show interesting  
126 indications that monthly-high vaccinees behave similarly to DFx, with trends towards high  
127 levels following the final vaccination (**Figures 1E, G**).

128

129 Given our interest in serum antibody maintenance over time – which may be modulated  
130 independently from changes in magnitude of the peak responses – we next calculated the fold  
131 change for each of the isotypes and subclasses between the peak response 2-weeks post  
132 final vaccination (Day 70 or Day 196) and the 6-month time point (Day 240 or 366), which had  
133 greater statistical power than the 1.5-year time point due to sample availability (**Figure 1H**).  
134 This clearly visualised the slower decay in total IgG, as reported previously (1), and IgG1 in  
135 the DFx vaccinees but also detected a significant difference in all other isotypes and  
136 subclasses between DFx vaccinees and (pooled) monthly regimen vaccinees – most  
137 convincingly for IgG3, IgA, IgA1 and IgM. This is an interesting indication that while DFx may  
138 not increase the magnitude of these responses, there may be an improvement in serum  
139 antibody response maintenance. Of note, IgG4 is the only isotype or subclass measured  
140 where decay is significantly faster with the DFx regimen – a signal which is largely driven by  
141 the unusual kinetics in the monthly-high vaccinees (**Figure 1G; Supplemental Figure 2E**).

142



143  
 144

145 **Figure 1. Antigen-specific B cell and Ig post-vaccination kinetics in DFx and**  
 146 **monthly dosing regimens.**


147 PBMC from pre-vaccination (Pre-vacc.), and 1-, 2-, 4-, and 12-weeks post final vaccination  
 148 time points were enriched for B cells and then stained with phenotypic markers and analysed  
 149 by flow cytometry. Frequencies of P<sub>f</sub>RH5-specific mBCs were defined as CD19+CD21+CD27+IgG+IgM-  
 150 cells within the live lymphocyte population that stained for monobiotinylated-P<sub>f</sub>RH5 conjugated to  
 151 streptavidin-PE (gating strategy shown in



152 **Supplemental Figure 1A**). Frequencies of PfRH5-specific mBCs were compared between  
153 (A) samples from a heterologous viral vector trial (ChAd63-MVA; ChAd63-PfRH5 prime, MVA-  
154 PfRH5 boost (10, 11) and the protein/AS01<sub>B</sub> trial, or (B) between monthly regimen vaccinees  
155 and DFX vaccinees within the protein/AS01<sub>B</sub> trial. (C) Spearman correlation analysis was  
156 performed between the frequency of PfRH5-specific mBCs 4-weeks after the final vaccination  
157 and the concentration of anti-PfRH5 serum IgG at the same time point (protein/AS01<sub>B</sub>  
158 vaccinees only). Vaccinees were included in these PBMC analyses based on sample  
159 availability. (A) ChAd63-MVA/ protein/AS01<sub>B</sub>: Pre-vacc.  $n = 15/18$ ; 1-week post final  
160 vaccination  $n = 10/0$ ; 2-week  $n = 0/25$ ; 4-week  $n = 15/29$ ; 12-week  $n = 13/25$ . (B) Monthly /  
161 DFX within protein/AS01<sub>B</sub> trial: Pre-vacc.  $n = 15/3$ ; 2-week  $n = 16/9$ ; 4-week  $n = 19/10$ ; 12-  
162 week  $n = 17/8$ . (A-B) Comparisons were performed by Mann-Whitney tests. Whiskers denote  
163 5<sup>th</sup> and 95<sup>th</sup> percentiles. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*\*  $p < 0.0001$ . (C) Sample size, Spearman  
164  $r$ , and  $p$  value are annotated on the graph. Each triangle represents one vaccinee and purple  
165 triangles indicate DFX vaccinees. Anti-RH5.1 FL (full length RH5.1) serum Ig was assayed by  
166 standardised ELISA to report (D) IgG1, (E) IgG2, (F) IgG3, and (G) IgG4 at key time points  
167 (Days 0, 14, 28, 42, 56/182, 70/196, 84/210, 240/366, 696/822). (D-G) Sample sizes for these  
168 ELISAs varied by group and by time point. Monthly-low:  $n = 12$ , except Day 696 where  $n = 9$ .  
169 Monthly-medium:  $n = 12$ , except for Day 240 and Day 696 where  $n = 11$  and  $n = 10$ ,  
170 respectively. DFX:  $n = 12$ , except for Day 366 and Day 822 where  $n = 11$  and  $n = 7$ ,  
171 respectively. Monthly-high:  $n = 11$ , except for Days 70, 240 and 696 where  $n = 9$ ,  $n = 10$  and  
172  $n = 4$ , respectively. Graphs show medians and interquartile ranges. (H) Fold change in serum  
173 anti-PfRH5.1 FL Ig between 2-weeks after final vaccination (Day 70 for monthly regimen  
174 vaccinees, and Day 196 for DFX vaccinees) and 6-months after final vaccination (Day 240,  
175 Day 366). Monthly regimen/ DFX:  $n = 31/ 11$  with the exception of IgG4 where  $n = 18 /9$ .  
176 Comparisons were performed between DFX and monthly regimens with Mann-Whitney tests.  
177 Bars denote medians and error bars denote interquartile ranges. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p$   
178  $< 0.001$ , \*\*\*\*  $p < 0.0001$ . Full kinetics for IgA, IgA1, IgA2 and IgM, as well a stratified version  
179 of panel H are shown in **Supplemental Figure 2**.

180 **Systems serology feature set associated with DFx dosing includes increased**  
181 **FcRn-binding, IgG avidity, and proportion of bi-galactosylated IgG Fc glycans**

182 Our stratified antibody isotype and subclass immunokinetic data suggest a significant impact  
183 of DFx dosing on humoral immunogenicity. We therefore next extended these analyses using  
184 a systems serology pipeline to integrate data on Fc biophysical and functional characteristics,  
185 measuring a total of 49 parameters (see Methods (13, 14)). As previously described (1), in  
186 addition to quantification of post-vaccination plasma levels of PfRH5-specific antibodies of  
187 each major isotype and subclass (with a Luminex bead-based assay rather than ELISA as  
188 above) this approach extends the biophysical analyses to include characterisation of the  
189 glycosylation profile of the anti-PfRH5 IgG Fc domains, which is known to influence these Fc-  
190 mediated functions (15). To assess Fc-mediated functionality of PfRH5-specific antibodies,  
191 the systems serology platform incorporates evaluation of their capacity to bind Fc receptors  
192 (FcRs), and to activate monocytes, neutrophils, natural killer (NK) cells, as well as the  
193 complement cascade. Here, in initial univariate analyses, we observed regimen-dependent  
194 differences in Fc-mediated activation with intriguing trends towards *reduced* functionality in  
195 DFx as compared to the monthly-low or monthly-medium vaccinees (**Figure 2**). Specifically,  
196 PfRH5-specific Ig in plasma samples 2-weeks following the final vaccination initiated  
197 decreased antibody-dependent complement deposition (ADCD; **Figure 2A**), antibody-  
198 dependent neutrophil phagocytosis (ADNP; **Figure 2B**) and NK cell cytokine production  
199 (MIP1 $\beta$  or IFN $\gamma$ ; **Figure 2C**). No differences were observed in NK cell degranulation as  
200 measured by CD107a expression (**Figure 2C**) or antibody-dependent cellular (monocyte)  
201 phagocytosis (ADCP; **Figure 2D**). It was of interest to note that in each instance samples from  
202 monthly-high vaccinees performed comparably to DFx vaccinees. This suggested that there  
203 was possibly an impact of the 'high' 50 $\mu$ g first and second doses (shared by these two groups)  
204 on Fc-mediated functionality, independent from any effect of a DFx final booster.



205  
206

207 **Figure 2. Fc-mediated functionality of peak post-vaccination antigen-specific Ig in DFX and monthly dosing regimens.**

208 Plasma from pre-vaccination and 2-weeks following the final vaccination was assessed for the capacity of anti-PfRH5 Ig to induce Fc-mediated  
 209 innate immune activation following incubation with PfRH5-coupled beads. The Fc-mediated functionality of post-vaccination anti-PfRH5 Ig was  
 210 compared between dosing regimen with respect to (A) antibody-dependent complement deposition (ADCD), (B) antibody-dependent neutrophil  
 211 phagocytosis (ADNP), (C) NK cell activation, and (D) antibody-dependent cellular (monocyte) phagocytosis (ADCP). (A) Beads were incubated  
 212 with guinea pig complement and C3 complement deposition was detected by staining with an anti-C3 fluorescent antibody and reported with the

213 median anti-C3 fluorescence intensity (MFI) of each sample. **(B)** Neutrophils were isolated from fresh blood and incubated with beads, then  
214 stained to define neutrophils as SSC<sup>hi</sup>CD66b+CD14-CD3- cells. Induction of phagocytosis was compared by calculating phagocytic scores as (%  
215 bead-positive cells) x (gMFI of bead-positive cells) / (10 x gMFI of the first bead-positive peak). **(C)** NK cells were purified from buffy coats and  
216 incubated with antigen-coated ELISA plates, then stained to define NK cells as CD56+CD3- cells. Activation was measured as the percentage  
217 of NK cells expressing MIP1 $\beta$ , CD107a, or IFN- $\gamma$  as detected by fluorescent antibodies. **(D)** The functional capacity of pre-/post-vaccination  
218 plasma to induce antibody-dependent monocyte phagocytosis was compared based on the capacity of anti-PfRH5-bound beads to induce  
219 phagocytosis by the THP-1 (monocyte) cell line. Phagocytic score of each sample = (% bead-positive cells) x (geometric median fluorescence  
220 intensity [MFI]) / (10x MFI of first bead-positive peak). Plasma was available from all vaccinees for inclusion in these analyses in technical  
221 duplicates. Pre-vaccination/ post-vaccination: Monthly-low  $n = 12/12$ ; monthly-medium  $n = 11/11$ ; DFx  $n = 11/11$ ; monthly-high  $n = 9/9$ .  
222 Comparisons between groups were performed by Kruskal-Wallis test with Dunn's correction for multiple comparisons. Whiskers denote 5<sup>th</sup> and  
223 95<sup>th</sup> percentiles. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*\*  $p < 0.0001$ .

224 To deconvolute these data, we took three approaches with our subsequent computational  
225 analyses of the complete systems serology datasets. First, we focused on our original  
226 research question by comparing all monthly versus DFx regimens (**Figure 3A-C**). Next, we  
227 limited this analysis to a direct comparison between the DFx and monthly-high vaccinees,  
228 these differ only in their final vaccination and are thus optimal comparators (DFx versus  
229 monthly-high; **Figure 3D-F**). Finally, we addressed the new hypothesis raised by the univariate  
230 Fc functional data and compared the monthly-low and monthly-medium regimens to the  
231 monthly-high and DFx regimens (**Figure 3G-I**). The computational pipeline in each instance  
232 consisted of performing a partial least-squares discriminant analysis (PLS-DA) using features  
233 selected via least absolute shrinkage and selection operator (LASSO; **Figure 3A-B, D-E, G-**  
234 **H**), and finally building Spearman correlation networks to reveal additional serology features  
235 significantly associated with the selected features (**Figure 3C, F, I**). Parallel computational  
236 analyses correcting for total anti-RH5 IgG yielded comparable results as expected (data not  
237 shown), given there were no significant differences between regimens at the 2-week post-  
238 vaccination time point (16).

239

240 The first analysis indicates a feature set able to discriminate between DFx and monthly  
241 regimens: FcRn-binding, IgG avidity, proportion of three different Fc glycans (G1FBG2, G2S2,  
242 G2S2F), IgG4 (all higher in DFx vaccinees); and IgG3, Fc $\alpha$ R-binding, ADCD, and ADCP, and  
243 G1S1F glycan (all higher in monthly regimen vaccinees; **Figure 3B; Supplemental Figure**  
244 **3**). The co-correlate network additionally detects a significant negative association between  
245 G2S2 and both NK cell (MIP1 $\beta$  and IFN $\gamma$ ) and complement cascade activation (**Figure 3C**).  
246 Conversely, ADCD and ADCP are associated with the monthly regimens, as suggested by the  
247 univariate data (**Figure 2**).










248

249 With respect to the second analysis, direct comparison of the DFx regimen with only the  
250 monthly-high regimen showed that increased FcRn-binding, IgG avidity, G2S2F and G2B  
251 glycans, alongside decreased IgG3, ADCD, and G2S1F glycan, were able to significantly

252 discriminate DFx vaccinees (**Figure 3E; Supplemental Figure 3**). The corresponding co-  
253 correlate network also identified positive correlations between FcRn-binding and FcR2B- or  
254 FcR3AV-binding, as well as correlations between G2S2F and G2S2 (positive) and FcR3AV-  
255 binding (negative).

256

257 Finally, the computational analyses identified increased FcRn-binding, IgG2 and IgG4, in  
258 addition to decreased IgM, ADCD, Fc $\alpha$ R-binding, and G2F glycan as the significant feature  
259 set to discriminate the ‘high’ dose vaccinees (**Figure 3H**). To note, the FcRn-binding signature  
260 in this analysis is attributable only to the DFx samples: FcRn-binding levels separate DFx vs  
261 monthly-high (**Figure 3E**) and removing FcRn-binding from the feature set, considered when  
262 separating lower vs higher dose groups, does not impact separation (data not shown). The  
263 selected features truly elevated in ‘high’ dosing are thus IgG2 and IgG4. This is consistent with  
264 the divergent IgG subclass immunokinetics analysed by ELISA described above (**Figure 1D-**  
265 **G**). No further correlations were identified in the co-correlates model with any of the three  
266 parameters elevated in the ‘high’ dose groups (**Figure 3I**).



268 **Figure 3. Systems serology computational analyses to define Ig feature sets that distinguish DFx from monthly dosing**  
269 **regimen.**

270 Partial least-squares discriminant analysis (PLS-DA) was performed with univariate read-outs from the systems serology analyses to compare  
271 DFx and monthly dosing regimens. Significant features were chosen via the LASSO feature selection algorithm and those chosen in at least 80%  
272 of 100 repetitions were used to build PLS-DA classifiers (**A-B**). Correlation networks were built to reveal additional serology features significantly  
273 associated with the selected features. Serology features significantly ( $p < 0.05$ , after a Benjamini-Hochberg correction) correlated via Spearman  
274 correlation ( $r_s > |0.7|$ ) were selected as co-correlates (**C**). The gradient colour of edges represents correlation value between the features,  
275 represented as nodes. Nodes are coloured according to selected status, with grey nodes as selected features and white nodes as co-correlate  
276 features. This approach was also used to directly compare DFx vaccinees with monthly-high (**D, E, F**) and DFx/ monthly-high vaccinees with  
277 monthly-low/ monthly-medium regimens (**G, H, I**). Line style (solid vs hash) of features in (**B, E, H**) relates to group with significant increase in  
278 that feature with 95% confidence interval. Models had cross-validation accuracies of 0.85 (**A**), 0.74 (**D**), and 0.83 (**G**), with comparisons to null  
279 models generated by random feature selection ( $p = 0.01$ ,  $p = 0.09$ ,  $p = 0.01$  respectively) or permuted labels ( $p < 0.01$ ,  $p = 0.04$ ,  $p < 0.01$   
280 respectively) being significant for all but comparison to a null model built with randomly selected features in DFx vs monthly-high vaccinees. This  
281 is likely due to the limited number of samples and the high correlations between selected features and non-selected features (**F**). LV: latent  
282 variable; ADCD: antibody-dependent complement deposition; ADCP: antibody-dependent cellular (monocyte THP-1) phagocytosis; ADNP:  
283 antibody-dependent neutrophil phagocytosis; ADNKA: antibody-dependent NK cell activation. Monthly-low:  $n = 12$ . Monthly-medium:  $n = 11$ . DFx:  
284  $n = 12$ , Monthly-high:  $n = 9$ .



285 Single cell RNA sequencing indicates higher proportion of plasma cells in  
286 monthly boosting regimen antigen-specific B cell population 2-weeks following  
287 final vaccination as compared to DFX dosing regimen

288 Taken all together, and alongside previously published complementary observations on serum  
289 anti-PfRH5 IgG avidity and longevity (1), the above data indicate substantial quantitative and  
290 qualitative differences between the PfRH5-specific humoral responses following monthly or  
291 DFX regimens. These results infer disparate B cell activation following the final vaccination,  
292 with downstream impact on the phenotype and longevity of antibody-secreting B cells.

293

294 While we had already shown that the DFX regimen induces a higher frequency of circulating  
295 CD19+IgG+ PfRH5-specific B cells (memory cells as shown in **Figure 1B**), it was not clear  
296 whether there were any qualitative differences within this population that might explain  
297 differences in the humoral response described above. To address this, we performed scRNA-  
298 seq with single cell sorted CD19+IgG+ PfRH5-specific B cells from  $n=4$  monthly-high  
299 vaccinees and  $n=3$  DFX vaccinees using a method based on Smart-Seq v4 for Ultra Low Input  
300 RNA. The post-vaccination time point with the highest frequency of PfRH5-specific cells (2-  
301 weeks after final vaccination; **Figure 1B**) was selected to maximise the number of cells  
302 available for sequencing. The range of frequencies of PfRH5-specific B cells within the live,  
303 CD19+IgG+ population acquired during sorting (**Figure 4A**; monthly regimen 0.6-1.9%, DFX  
304 regimen 1.7-8.9%) were comparable to those previously observed (**Figure 1B**).

305

306 We first explored the heterogeneity in gene expression across all vaccinees within Seurat  
307 (**Figure 4B-J**). A total of 209 cells from monthly-high vaccinees and 214 cells from DFX  
308 vaccinees were included in this analysis. Following normalisation of data, we identified the ten  
309 genes with the highest variance across the entire sample set: MZB1, KNG1, LEO1, EAF2,  
310 UBXN8, P2RY12, ZNF234, MRPL35, TNFRSF17, IGKV1-39. Two of these genes are  
311 noteworthy for their associations with plasma cells that could be highly relevant for


312 understanding our humoral data set: MZB1 and TNFRSF17. MZB1 – also known as Plasma  
313 cell-induced ER protein (pERp1) – is a key effector of the transcription factor B that regulates  
314 terminal plasma cell differentiation (Blimp1) and is of particular interest due to its reported  
315 roles in antibody secretion, as well as plasma cell differentiation and migration to the bone  
316 marrow (17-24). TNFRSF17 – also known as BCMA – is the APRIL and BAFF receptor which  
317 is restricted to mature B cells and plasma cells (including both short-lived and long-lived) and  
318 required for survival of LLPCs in the bone marrow (25-27).

319

320 Next, we ran a PCA to identify the number of principal components appropriate for  
321 downstream clustering and visualisation with UMAP (**Figure 4B**). Running UMAP on these  
322 principle components, we observe phenotypically distinct populations of cells (**Figure 4C**) one  
323 of which appeared to be enriched for monthly-high vaccinee cells (cluster 4; **Figure 4C-D**).  
324 The top 5 significant genes associated with this cluster (based on fold change) are IGHG2 (Ig  
325 Heavy Constant Gamma 2; i.e. heavy chain of IgG2), RP11-731F5.2 (LincRNA), IGLC1 (Ig  
326 Lambda Constant Region 1), IGLJ1 (Ig Lambda Joining 1), and IGLL5 (Ig Lambda Like  
327 Polypeptide 5; **Supplemental Table 1**). The other clusters are comprised more evenly of  
328 monthly-high regimen and DFx cells with the top genes for each as follows: MS4A1 (CD20)  
329 and YPEL5 for Cluster 0; GAREML and PSD for Cluster 1; LDHA and CCR7 for Cluster 2;  
330 and, MT-RNR2 and MUC3A for Cluster 3 (top 5 genes for each shown in **Supplemental Table**  
331 **1**). While these gene rankings don't suggest specific B cell subsets for clusters 0-3, the  
332 prevalence of Ig genes in cluster 4 suggest this may be an (antibody-producing) plasma cell  
333 population. A heat map visualisation of the top 50 most differentially expressed genes between  
334 the clusters additionally highlights increased expression among nearly all cells in cluster 4 of  
335 further genes with potential relevance to Ig production or plasma cell phenotype. In addition  
336 to MZB1 and TNFRSF17, this group of genes includes multiple encoding proteins with  
337 functions related to the secretory pathway or protein production and trafficking e.g. PPIB,  
338 ARF3, FKBP11, SEC11C, SSR4, BLOC1S5, and TXNDC5 (**Figure 4E**).

339

340 To further probe this potential cluster 4 plasma cell phenotype, we plotted several of the genes  
341 of interest as flagged above that should have clear positive or negative expression in a plasma  
342 cell population: MS4A1 (CD20), CCR7, MZB1 and TNFRSF17. CD20 and CCR7 are both  
343 downregulated during plasma cell differentiation (20, 28-30) and indeed here we see  
344 decreased expression in cluster 4 as compared to clusters 0-3 (**Figure 4F-G**). Given that the  
345 absence of CD20 expression on a B cell is the canonical definition of an antibody-secreting  
346 cell (though other marker combinations can be used e.g. CD27<sup>hi</sup>CD38<sup>hi</sup> (28)), this is strong  
347 evidence that cluster 4 is a plasma cell population. CD20 expression has also been used  
348 previously to differentiate antibody-secreting (plasma) cells from other probe-specific B cells  
349 – defined as activated B cells (ABCs) – following influenza vaccination (31). Conversely, both  
350 MZB1 and TNFRSF17 – both with clear plasma cell biological roles – are expressed almost  
351 exclusively in cluster 4 (**Figure 4H-I**). Finally, scoring each of the clusters based on expression  
352 of a previously identified set of genes upregulated in plasma cells as compared to other B cells  
353 (“TARTE\_PLASMA\_CELLS\_VS\_B\_LYMPHOCYTE\_UP” (32)) also yields a strong  
354 statistically significant difference between cluster 4 and the other clusters (**Figure 4J**).



355  
356  
357  
358  
359

Figure 4. Single cell RNA sequencing of antigen-specific B cells from DFx and monthly-high dosing vaccinees.

PBMC from pre-vaccination (Pre-vacc.), and 2-weeks post final vaccination in DFx vaccinees ( $n=3$ ) and monthly-high vaccinees ( $n=4$ ) were enriched for B cells and then stained with phenotypic markers for single cell sorting of antigen-specific B cells as defined as: live CD19+IgG+

360 lymphocytes that co-stained for monobiotinylated-PfRH5-PE and monobiotinylated-PfRH5-APC (gating strategy shown in **Supplemental Figure**  
361 **1A**). Frequencies of post-vaccination PfRH5-specific B cells from the samples sorted were comparable with previous data (**A**). Libraries were  
362 sequenced following a Smart-Seq v4 and Nextera XT pipeline on a HiSeq4000. Variation in gene expression within the 7 samples was explored  
363 in Seurat by (**B**) PCA analysis of DFX as compared to monthly-high regimen, (**C**) UMAP with 5 clusters, (**D**) UMAP with 5 clusters with dosing  
364 regimen identity overlaid, and (**E**) heat map of the top 50 most differentially expressed genes by cluster. Expression of genes of interest identified  
365 were then compared between cluster 4 and the other clusters by Wilcoxon Rank Sum Test with Bonferroni correction to give adjusted  $p$  values  
366 ( $p_{adj}$ ): (**F**) MS4A1 (CD20), (**G**) CCR7, (**H**) MZB1, and (**I**) TNFRSF17. Expression of a plasma cell gene set  
367 (“TARTE\_PLASMA\_CELLS\_VS\_B\_LYMPHOCYTE\_UP” (32)) was also compared between cluster 4 and the other clusters by Kruskal-Wallis  
368 test (**J**). Finally, gene set enrichment analysis with the TARTE\_PLASMA\_CELLS\_VS\_B\_LYMPHOCYTE\_UP gene set was run with the 5,115  
369 significant genes from DESeq2 analyses comparing gene expression in PfRH5-specific CD19+IgG+ B cells from monthly-high and DFX regimen  
370 vaccinees (top twenty genes shown in Table 2). NES: normalised enrichment score; Leading Edge: subset of genes from gene set contributing  
371 most to the enrichment signal.

372 We next proceeded to validate the indication from this single cell Seurat analysis that there  
373 was a discrepancy in the proportion of plasma cells (cluster 4) within PfRH5-specific B cells  
374 by dosing regimen using differential gene expression analyses between monthly-high and DFx  
375 regimen vaccinees. A total of 5,115 genes were differentially expressed (adjusted p value  
376 (padj) <0.05); the 30 significant genes with the greatest fold change in expression are  
377 presented in **Table 2**. Genes with increased expression in cells from monthly-high as  
378 compared to DFx vaccinees include MZB1, IGJ (also known as J Chain and associated with  
379 plasma cells (33), HLA-DQA2, and HLA-DRA. Of the other 25 genes, 17 were immunoglobulin  
380 heavy or light chain likely indicating increased Ig production. To note, while it is also possible  
381 that the Ig genes merely reflect differences between vaccinees in Ig gene usage, a similar  
382 increase in different Ig heavy or light chains is not observed in the DFx vaccinees. Only one  
383 gene downregulated in monthly-high vaccinees as compared to DFx is included in the top 30  
384 differentially expressed genes: ACSM2B, which is involved in first step of fatty acid  
385 metabolism. As germinal centre B cells primarily utilise fatty acid metabolism to meet their  
386 metabolic needs – unlike other proliferating B cells (34, 35) – this could be indicative of a  
387 difference in germinal centre kinetics and output between the two regimens.

Positive log <sub>2</sub> (FC) genes for G4 vs DFx			Negative log <sub>2</sub> (FC) genes for G4 vs DFx		
Gene Name	log <sub>2</sub> (FC)	P-adj	Gene Name	log <sub>2</sub> (FC)	P-adj
MZB1	3.80	2.69E-69	ACSM2B	-1.90	5.30E-09
IGKV4-1	3.61	2.09E-48			
IGJ	2.87	5.66E-27			
IGLV3-1	2.85	4.33E-17			
HLA-DQA2	2.78	2.49E-39			
IGHV3-11	2.65	1.19E-14			
IGHV3-72	2.50	5.75E-13			
IGHV3-21	2.45	2.34E-12			
IGHG2	2.45	2.60E-29			
RASSF6	2.43	5.87E-25			
IGHG3	2.43	2.21E-24			
IGHG1	2.35	2.04E-32			
HLA-DRA	2.34	2.91E-19			
IGHV3-7	2.32	2.68E-11			
CD1C	2.25	1.99E-10			
SAMD9L	2.22	2.75E-11			
IGHV3-23	2.22	2.02E-10			
IGHV3-15	2.21	2.34E-10			
IGLV1-40	2.18	7.42E-10			
IGKV1-5	2.17	9.62E-10			
IGHA1	2.09	1.78E-23			
THAP9	2.06	6.49E-09			
IGKV3-20	2.04	3.27E-09			
SELPLG	2.03	8.33E-21			
IGLV6-57	2.01	1.09E-10			
KNG1	2.00	4.03E-23			
RWDD2A	2.00	4.09E-10			
IGLV7-46	1.94	7.20E-08			
CENPW	1.92	4.05E-09			

388  
389

390 **Table 2. Differentially expressed antigen-specific B cell genes between DFx**  
391 **and monthly-high dosing vaccinees.**

392 Differentially expressed genes between DFx and monthly dosing samples were identified by  
393 DESeq2 and filtered to remove pseudogenes, LincRNA, IncRNA, and non-significant genes  
394 as defined as padj > 0.05. Genes were then ranked by fold change to show the top thirty genes  
395 differentially expressed between monthly-high regimen and DFx.

396 Log<sub>2</sub>(FC): log fold change between monthly-high regimen and DFx; padj: adjusted *p* value  
397 after Benjamini-Hochberg correction for multiplicity of testing.

398 Further exploration of the significantly differentially expressed genes by gene set enrichment  
399 analysis (GSEA) with the Kegg mSigDB gene sets indicated significant enrichment  
400 ( $p_{adj} < 0.05$ ) in 10 pathways, including: cell adhesion molecules, protein export, and intestinal  
401 immune network for IgA production (**Supplemental Table 2**). Protein secretion and mTORC1  
402 signalling (also related to protein secretion) were similarly flagged during Hallmark GSEA but  
403 no pathway reached statistical significance with an adjusted p value (**Supplemental Table 3**).  
404 A third GSEA with the plasma cell gene set used in **Figure 4J** – here run on all significantly  
405 differentially expressed genes rather than just cluster 4 – also showed a significant enrichment  
406 ( $p < 0.0001$ ; NES=2.24; **Figure 4K**).

407

408 Initially, the remaining disease-related pathways (**Supplemental Table 2**) do not seem to be  
409 of clear relevance to vaccine-specific B cell responses. However, the leading edges of each  
410 gene set (i.e. the subset of genes contributing most to the enrichment signal) reveal a central  
411 role for HLA class II genes in all pathways not otherwise linked to protein – putatively,  
412 immunoglobulin – production. While data on HLA-DQ and HLA-DP genes is scarce, HLA-DR  
413 is often used as a marker of activation, particularly of proliferating plasmablasts (i.e. SLPCs)  
414 as opposed to more mature LLPCs or other mBC phenotypes (28, 36, 37). The dominance of  
415 HLA class II genes in the leading edges of pathways enriched in monthly regimen vaccinees  
416 is therefore consistent with a higher proportion of SLPCs within the circulating PfRH5-specific  
417 B cell pool 2-weeks following final vaccination as suggested by the Seurat analyses (**Figure**  
418 **4**) and differentially expressed genes highlighted in the original DESeq2 analyses (**Table 2**).








419

#### 420 [PfRH5-specific B cells show greater CDR3 somatic hypermutation in DFx](#) 421 [vaccinees as compared to monthly regimen vaccinees](#)

422 As the polyclonal serum anti-PfRH5 IgG antibody analyses demonstrated higher avidity in the  
423 DFx vaccinees (1), we were also interested to interrogate the BCR repertoire of the circulating  
424 PfRH5-specific B cells to determine if there were differences in percentage germline mutation



425 or other divergent trends in clonotypes. Following analysis with the MiXCR pipeline to extract  
426 CDR3 sequences from the scRNA-seq data set, we compared CDR3 length as well as heavy  
427 and light chain CDR3 V-(D)-J percentage mutation from germline between monthly-high and  
428 DFx vaccinees. Here, we observe minimal differences in CDR3 length (**Figure 5A**), but  
429 increased somatic hypermutation in the DFx regimen PfRH5-specific cells as compared to  
430 those from the monthly-high regimen (**Figure 5B-C**). Analysis of heavy chain V gene usage  
431 showed substantial variation between individuals (**Supplemental Figure 4**) but broadly similar  
432 patterns when comparing monthly-high regimen and DFx vaccinee groups (**Figure 5D-E**). A  
433 total of 40 V genes were detected in CDR3 heavy chains, with 5 of the 6 top genes the same  
434 in both monthly-high and DFx vaccinees (IGHV4-39, IGHV4-31, IGHV3-23, IGHV3-21, and  
435 IGHV3-33). Finally, hierarchical clustering was performed with heavy chain CDR3 amino acid  
436 sequences using Geneious Tree Builder and visualised as unrooted dendrograms (**Figure 5F-**  
437 **G; Supplemental Figure 4**). Three clusters were observed in both monthly-high regimen  
438 (**Figure 5F**) and DFx vaccinees (**Figure 5G**), as well as individual vaccinees (**Supplemental**  
439 **Figure 4**).



441 **Figure 5. CDR3 sequence analysis of PfrH5-specific B cells in DFx and monthly-high dosing vaccinees.**  
442 PBMC from pre-vaccination (Pre-vacc.), and 2-weeks post final vaccination in DFx vaccinees ( $n=3$ ) and monthly-high vaccinees ( $n=4$ ) were  
443 enriched for B cells and then stained with phenotypic markers for single cell sorting of antigen-specific B cells as defined as: live CD19+IgG+  
444 lymphocytes that co-stained for monobiotinylated-PfrH5-PE and monobiotinylated-PfrH5-APC (gating strategy shown in **Supplemental Figure**  
445 **1A**). Libraries were sequenced following a Smart-Seq v4 and Nextera XT pipeline on a HiSeq4000. CDR3 sequences were extracted using the  
446 MiXCR pipeline to compare heavy and light chain CDR3 lengths (**A**), and average percentage germline identity for V-D-J or V-J heavy chain (**B**)  
447 and V-J light chain (**C**) sequences. Comparisons were performed by Mann-Whitney tests. Whiskers denote 5<sup>th</sup> and 95<sup>th</sup> percentiles. \*  $p < 0.05$ , \*\*  
448  $p < 0.01$ , \*\*\*\*  $p < 0.0001$ . Heavy chain (HC) V gene usage is reported for monthly-high (**D**) and DFx (**E**) vaccinees. The top five HC V genes  
449 shared between groups (IGHV3-21, IGHV3-23, IGHV3-33 IGHV4-31, and IGHV4-39,) are emphasised in the charts and underlined in the key.  
450 Hierarchical clustering was performed on CDR3 HC amino acid sequences and visualised as dendrograms for monthly-high vaccinees (**F**), and  
451 DFx vaccinees (**G**). The first three branches are labelled in each dendrogram with branch length (distance between internal nodes) i.e.  
452 substitutions per amino acid.

## 453 Limitations

454 As is often true for scRNA-seq analyses, our sample size is relatively small. Here, we  
455 compared gene expression and BCR repertoires between  $n=4$  monthly regimen vaccinees  
456 and  $n=3$  DFx vaccinees. Similarly, while the sample size for the systems serology work was  
457 higher ( $n=32$  monthly regimen;  $n=12$  DFx) our conclusions from these data sets could again  
458 be strengthened with future replication studies with further vaccinees. Reproducing our  
459 findings with similar dosing regimens but different antigens would be particularly of interest to  
460 confirm translatability of our findings.

461

462 It is also important to note two potential limitations associated with the use of the PfRH5 probes  
463 and the gating strategy used to define PfRH5-specific B cells for the scRNA-seq pipeline. First,  
464 while we routinely observe negligible background probe staining with Day 0 samples (**Figure**  
465 **1; Supplemental Figure 1**) we did not clone monoclonal antibodies (mAbs) from BCRs of  
466 single sorted cells and screen to verify PfRH5 specificity. It is therefore possible that a minority  
467 of cells included in the sequencing analysis are not truly PfRH5-specific. Second, while  
468 previous work in our lab (data not shown) has demonstrated that CD19+IgG+ gating, during  
469 single cell sorting, facilitates clear differentiation between probe-negative and probe-positive  
470 populations, it is important to note that any downstream analyses consequently exclude any  
471 CD19- B cell populations as well as IgM+ or IgA+ subsets. Likewise, IgG+ plasma cell  
472 populations with very low BCR expression may have been missed from the IgG+ gate.

## 473 Discussion

474 In this study we have interrogated the circulating antigen-specific Ig and B cell responses  
475 following immunisation with either monthly (0-1-2 month) or DFx (0-1-6 month) dosing  
476 regimens using the same vaccine. To the best of our knowledge, this is the first detailed  
477 exploration of B cell and humoral responses to a vaccine regimen that significantly improves  
478 Ig durability in humans. We observe that the DFx regimen greatly enhances the longevity of  
479 the IgG1 component of the total IgG response, with additional indications of improved serum  
480 maintenance across multiple other subclasses and isotypes (IgG3, IgA, IgA1, IgM). While the  
481 serum antibody kinetics are unique to DFx, analysis of peak Ig responses (2-weeks following  
482 final vaccination) suggested some similarities with the monthly regimen group with the same  
483 'high' (50µg) first and second doses (monthly-high: 50-50-50µg). Specifically, these two  
484 groups of vaccinees shared increased IgG2 and IgG4 titres, in comparison to the monthly-low  
485 and monthly-medium groups. Univariate analyses of FcR-mediated functionality at the peak  
486 post-vaccination time point indicated other similarities between DFx and monthly-high  
487 regimen, with significantly lower activation of ADCD, and trends towards reduced ADCP and  
488 antibody-dependent NK cell activation as compared to monthly-low / monthly-medium.  
489 Systems serology computational analyses indeed identified IgG2 and IgG4 as components of  
490 the feature set that was associated with 'high' DFx / monthly-high.

491  
492 An increase in antigen-specific IgG4 following DFx has been observed previously with the  
493 PfCSP-based pre-erythrocytic malaria vaccine RTS,S (0-1-7mo in this instance; Fx017M)  
494 when compared to a monthly 0-1-2mo regimen, as well as an IgG4-related decrease in ADCP  
495 (38). In the context of PfCSP-mediated vaccines it appears that IgG4 inhibition of  
496 opsonophagocytosis has a positive impact on protection, potentially related to a sporozoite  
497 immune escape mechanism, but whether this would also be true for blood-stage parasites is  
498 unknown. The authors comment that the prevailing view of chronic exposure to antigen as a  
499 driver of IgG4 (reviewed in (39, 40)) seems to conflict with their data, whereas the relevance

500 appears clearer in our PfRH5 analyses whereby IgG4 is increased in both the DFx and  
501 monthly-high groups primed with the highest 50 µg dose of RH5.1 vaccine. To the best of our  
502 knowledge, there are no published data on the impact of relatively 'high' protein vaccine dosing  
503 on induction of an IgG2 response and the interpretation of these results is not clear.

504

505 With respect to the DFx regimen specifically, the associated systems serology feature set, as  
506 compared to all monthly regimen groups, consisted of increased FcRn-binding, IgG avidity,  
507 IgG4, and proportions of three galactosylated Fc glycans (G1FBG2, G2S2, G2S2F) and  
508 decreased IgG3, ADCD, ADCP, FcαR-binding, and G1S1F galactosylated Fc glycan. This  
509 was refined when analyses were limited to a DFx versus monthly-high regimen comparison:  
510 elevated FcRn-binding, IgG avidity, G2S2F and G2B Fc glycans, and decreased ADCD, IgG3,  
511 and G1S1F glycan. Our data therefore suggest both a negative impact of 'high' first and  
512 second doses (e.g. reduced capacity to induce ADCD) and a positive impact of the delayed  
513 fractional final dose (e.g. increased avidity and FcRn-binding) on the antigen-specific Ig  
514 response with the DFx regimen. This concept of a potential detrimental impact of excessive  
515 antigen or antigen saturation on vaccine immunogenicity has previously been proposed by  
516 others and merits further investigation, as do DFx regimens using lower priming doses (9, 41).

517

518 The avidity signal for DFx bolsters the conclusions of our previously published trial report with  
519 a different assay (1), while the glycan, subclass and FcRn-binding data provide novel insights  
520 into the profound modulation of the humoral response that can be achieved through  
521 modification of dosing regimen. The importance of improved avidity in the specific context of  
522 PfRH5-based vaccines is uncertain given previous work with mAbs (derived from samples  
523 from the viral vector trial) indicated that the speed of antibody-binding, rather than avidity, is  
524 more relevant for *in vitro* anti-parasitic functionality (1, 42). However, improved antibody avidity  
525 is associated with increased protection against other pathogens (including pre-erythrocytic *P.*  
526 *falciparum* malaria (7, 43-46)) and thus these DFx data may be of great interest to other  
527 vaccine development programmes. Importantly, this serum avidity improvement is supported

528 by CDR3 sequence analysis of single cell sorted PfrH5-specific B cells where greater somatic  
529 hypermutation was observed in DFx vaccinees as compared to monthly regimen vaccinees.  
530 Further studies are also underway to interrogate the binding kinetics of mAbs derived from  
531 monthly regimen and DFx RH5.1/AS01<sub>B</sub> vaccinees and the relationship to the *in vitro*  
532 functional correlate of protection (growth inhibitory activity [GIA] (1)).

533

534 The biological implication of increased capacity of post-vaccination Ig to bind to FcRn is  
535 noteworthy due to the central role of FcRn-binding in antibody longevity through promoting  
536 recycling rather than lysosomal degradation of IgG in circulation; durability of mAbs can be  
537 enhanced by modifying the Fc to improve FcRn-binding (47, 48). FcRn-binding can also be  
538 ameliorated with more highly galactosylated Fc glycans (15) and, consistent with this, the  
539 systems serology signature associated with the DFx samples included increased proportions  
540 of two bi-galactosylated glycan moieties (G2B and G2S2F). Similarly, and consistent with the  
541 avidity data, is evidence from influenza vaccine antibody analyses demonstrating increases in  
542 sialylation (e.g. as in G2S2F) correlated with generation of higher affinity antibodies (15, 49).  
543 It is therefore possible that in DFx vaccinees there is an increase in expression of the  
544 glycosyltransferases responsible for adding galactose (B4GALT1) and sialic acid (ST6GAL1)  
545 with functional significance for FcRn-binding / longevity (galactose) and avidity (sialic acid).  
546 These hypotheses require further interrogation however, especially given the glycosylation  
547 changes are more specific than increases in all bi-galactosylated or bi-sialylated moieties. To  
548 note, although adjuvant selection can demonstrably impact peak antibody responses and  
549 antibody quality (including Fc glycans), evidence of any effect on antibody long-term  
550 maintenance is thus far limited to non-human primates (50, 51).

551

552 These changes in antigen-specific Ig quantity and quality thus suggest fundamentally different  
553 B cell responses following the third dose in DFx versus monthly regimens. Based on observed  
554 total IgG kinetics, we have previously hypothesised that the DFx regimen seeds a higher  
555 frequency of LLPCs in the bone marrow (1) but empirical data on direct detection of antigen-

556 specific B cells (of any phenotype) in circulation or in lymphoid tissue have not been reported.  
557 We therefore first measured the frequency of peripheral antigen-specific cells within the  
558 memory IgG+ B cell population. Here, we showed that the frequency of circulating antigen-  
559 specific B cells was significantly higher in DFx vaccinees at all time points measured.  
560 However, we do not expect that a higher magnitude B cell response alone could be  
561 responsible for the range of qualitative differences in the humoral response detailed above.  
562 We therefore proceeded to scRNA-seq as an agnostic approach to qualitative antigen-specific  
563 B cell analysis with the goal of detecting any indication of discrepancies in B cell kinetics or  
564 fate decisions between the two dosing regimens. In light of the potential confounding factor of  
565 'high' vs 'low' first and second doses, we restricted this analysis to DFx and monthly-high  
566 regimen.

567

568 Here, several pieces of data pointed to an increased proportion of plasma cells within the  
569 antigen-specific B cell population in monthly-high vaccinees, as compared to DFx. First, we  
570 identified a subpopulation of antigen-specific B cells that was almost exclusively comprised of  
571 cells from monthly-high vaccinees. This cluster was recognised as a plasma cell population  
572 due to the high expression of plasma cell markers MZB1 and TNFRSF17 (BCMA), negligible  
573 expression of MS4A1 (CD20) and CCR7, and significant enrichment for a pre-defined plasma  
574 cell gene set. Second, differential gene expression analysis (DESeq2) identified MZB1 as the  
575 gene with the highest fold change in expression between monthly-high and DFx samples, with  
576 18 of the other top 29 genes comprised of IGJ or Ig heavy and light chains – consistent with  
577 increased antibody secretion. Indeed, in a recent single cell atlas characterisation of human  
578 tonsillar B cell populations, MZB1, IGJ and IGH genes were all expressed most highly in the  
579 plasmablast population (52). Finally, KEGG gene set enrichment analysis with the significantly  
580 differentially expressed genes highlighted the protein export pathway as significantly  
581 upregulated in monthly-high B cells as compared to DFx B cells.

582



583 At first glance, these scRNA-seq results suggesting greater IgG+ plasma cell activation in  
584 monthly-high than Dfx are surprising, especially when anti-PfRH5 serum IgG levels are  
585 comparable between the two regimens at the peak time point used for this analysis (2-weeks  
586 post final vaccination (1)) and subsequently higher in Dfx vaccinees long-term. However,  
587 selection of a single time point provides only a plasma cell “snapshot” rather than longitudinal  
588 kinetics; it is entirely feasible that the Dfx response actually peaked between 2- and 4-weeks  
589 following final vaccination versus between 1- and 2-weeks with monthly-high. Furthermore,  
590 LLPCs exit later than mBCs in germinal centre development and, while this has been  
591 documented from 2-weeks post-vaccination onwards, it is possible that our scRNA-seq time  
592 point is better suited to mBC and SLPC detection as compared to (later) LLPCs (53-55).  
593 Accordingly, we propose that the Day 70 plasma cell signal in monthly-high vaccinees is  
594 derived predominantly from mBCs that have differentiated into short-lived plasma cells  
595 (SLPCs) following antigen re-exposure, rather than those that have returned to a draining  
596 lymph node and differentiated into LLPCs via germinal centre reactions. It is also likely that  
597 monthly regimen vaccinees still possessed PfRH5-specific germinal centres from the second  
598 vaccination at the time of the third and final booster which – alongside higher concentrations  
599 of anti-PfRH5 serum IgG at the time of vaccination – could have dampened new germinal  
600 centre responses (9, 56, 57). This is consistent with HIV vaccinology data from non-human  
601 primates where longer intervals between doses were associated with increased germinal  
602 centre B cell responses (58). Germinal centre-independent SLPC differentiation in monthly-  
603 high vaccinees would also be consistent with the observed lower CDR3 somatic  
604 hypermutation (and reduced serum IgG avidity) as compared to Dfx vaccinees.

605

606 Another factor relevant for reconciling the serum IgG and plasma cell data is possible variation  
607 in CD19 expression by different plasma cell populations. CD19 is a common marker for  
608 identifying human B cells, but it has also been reported to be downregulated on terminally  
609 differentiated bone marrow LLPCs as well as on a minority of circulating plasma cells following  
610 vaccination (59-62). If peripheral LLPCs or LLPC-precursors downregulate CD19 they would

611 not have been captured for the scRNA-seq pipeline by the CD19+IgG+ gating strategy if truly  
612 negative for CD19 (rather than CD19lo). This would again mean that the plasma cell  
613 population identified in our analyses is skewed to SLPCs, while any differences in germinal  
614 centre LLPC/precursor output between the two platforms are obscured. However, the  
615 significance or likelihood of circulating CD19- LLPCs and LLPC-precursors is unclear, given  
616 other reports of a putative LLPC-precursor population within the circulating CD19+  
617 compartment (63) and timing of CD19 downregulation only once cells reached the bone  
618 marrow (59).

619

620 Future clinical trials should therefore seek to more precisely define this plasma cell population  
621 kinetics with DFx versus monthly boosting and to confirm our hypothesised skew towards  
622 LLPC and SLPC subsets, respectively. This distinction is currently difficult given the lack of  
623 clear markers to resolve SLPCs from LLPCs / LLPC precursors in humans (reviewed in (64)),  
624 although data suggest the transcription factor Zbtb20 may be used to define LLPCs in mice  
625 ((65) no increased expression was observed in our putative SLPC population). Moving forward  
626 will rely on more frequent venous sampling following the final vaccination, ideally coupled with  
627 analysis of draining lymph node aspirates to directly monitor germinal centre formation /  
628 longevity and define peripheral biomarkers of plasma cell output (57, 66, 67). Bone marrow  
629 aspirates may also be of use to confirm a link between higher serum anti-PfRH5 IgG  
630 maintenance and presumed higher LLPC seeding in the DFx regimen, as well as with putative  
631 LLPC precursor populations.

632

633 It will also be of great interest to better understand the discrepancy between the results  
634 observed with DFx RH5.1/AS01<sub>B</sub> vaccination and similar Fx017M dosing with the RTS,S/AS01  
635 which gave greater protection than the monthly regimen in controlled human malaria infection  
636 (CHMI) studies (6-8, 41). Like with DFx RH5.1 dosing, the Fx017M RTS,S regimen increased  
637 IgG avidity and (bulk plasmablast, i.e. SLPC) B cell somatic hypermutation after final  
638 vaccination – which correlated with protection – but not magnitude of the IgG response as

639 compared to the monthly 0-1-2-month regimen (7). However, there was no apparent Fx017M-  
640 mediated benefit to Ig longevity and thus durability of vaccine-mediated protection (7). This is  
641 a critical distinction to understand in order to ensure relevance of DFX dosing to other antigens  
642 and pathogens. However, the failure of Fx017M to improve Ig serum maintenance could be  
643 related not to characteristics of the antigen, but of the platform; CSP is arrayed on a VLP which  
644 could potentially form immune complexes affecting LLPC development (68). Modelling data  
645 indeed indicate that IgG concentration and avidity are regulated independently by separate  
646 biological processes (69). Other discrepancies are also found with recently published systems  
647 serology analyses of monthly versus Fx017M dosing (70) where different trends were  
648 observed with Fx017M to those reported here with DFX.

649

650 In conclusion, the data presented here support the DFX regimen as a more promising dosing  
651 schedule as compared to more routine monthly dosing for optimising the humoral response  
652 against difficult pathogens like blood-stage malaria that require high, sustained titres for  
653 protection. The impact appears to be largely related to IgG1 but more subtle effects on other  
654 isotypes and subclasses are also present. Two hypotheses regarding the underlying  
655 mechanism of the improved plasma antibody longevity in the DFX schedule merit further  
656 exploration: increased recycling through enhanced FcRn-binding, and a potential shift in B cell  
657 fate from SLPC to LLPC following the delayed final dose. The mechanism for improved avidity  
658 with DFX is also likely linked to germinal centre kinetics, potentially related to competition for  
659 antigen which others have speculated is linked to the fractionation of the final dose rather than  
660 the delay (7, 41, 71, 72). Further clinical trials will therefore be needed to directly compare the  
661 impact of delayed boosting to the fractionation of the final dose, and also – for antigens other  
662 than PfRH5 such as PfCSP – to delineate the possible roles of antigen and vaccine delivery  
663 platform.

## 664 Methods

665

### 666 Resource availability

#### 667 Lead contact

668 Further information and requests for resources and reagents should be directed to and will be  
669 fulfilled by the Lead Contact, Carolyn Nielsen ([carolyn.nielsen@bioch.ox.ac.uk](mailto:carolyn.nielsen@bioch.ox.ac.uk)).

670

#### 671 Data and code availability

672 The scRNA-seq data generated during this study are available from the NCBI SRA database,  
673 BioProject accession number SUB10783850.

674

#### 675 Experimental model and subject details

676 This study focused on the comparison of immune responses between groups receiving  
677 different dosing regimens of PfRH5 protein (RH5.1) with AS01<sub>B</sub> adjuvant (ClinicalTrials.gov  
678 Identifier: NCT029271452 (1, 12); adjuvant provided by GSK). The clinical trial  
679 NCT029271452 from which samples were used for this study was approved by the Oxford  
680 Research Ethics Committee A in the UK (REC reference 16/SC/0345) as well as by the UK  
681 Medicines and Healthcare products Regulatory Agency (MHRA; reference 21584/0362/001-  
682 0001). All volunteers gave written informed consent.

683

684 Vaccine regimens are presented in **Table 1**. Antibody and Tfh cell responses to the different  
685 regimens have already been reported elsewhere (1, 10). Vaccinee age and sex were  
686 comparable between regimens and are summarised in **Table 1**. Not all vaccinees could be  
687 run in each of the assays in this study; specific sample sizes are specified in figure legends.

688

689 A second PfRH5 clinical trial with heterologous viral vectors (consisting of a ChAd63-PfRH5  
690 prime, followed by a MVA-PfRH5 boost) is also briefly referenced for comparison in **Figure 1**

691 (ClinicalTrials.gov Identifier: NCT02181088; (10, 11). This trial was also approved by the  
692 Oxford Research Ethics Committee A in the UK (REC references 14/SC/0120) as well as by  
693 the UK MHRA. All volunteers gave written informed consent.

694

## 695 Method details

### 696 P<sub>f</sub>RH5-specific B cell flow cytometry

697 Cryopreserved PBMC were thawed into R10 media (RPMI [R0883, Sigma] supplemented with  
698 10% heat-inactivated FCS [60923, Biosera], 100U/ml penicillin / 0.1mg/mL streptomycin  
699 [P0781, Sigma], 2mM L-glutamine [G7513, Sigma]) then washed and rested in R10 for 1h. B  
700 cells were enriched (Human Pan-B cell Enrichment Kit [19554, StemCell]) and then stained  
701 with viability dye FVS780 (565388, BD Biosciences). Next, B cells were stained with anti-  
702 human CD19-PE-Cy7 (557835, BD Biosciences), anti-human IgG-BB515 (564581), anti-  
703 human IgM-BV510 (563113), anti-human CD27-BV711 (564893), anti-human CD21-BV421  
704 (562966), as well as two fluorophore-conjugated P<sub>f</sub>RH5 probes. Preparation of the P<sub>f</sub>RH5  
705 probes has been published previously (10). In brief, monobiotinylated P<sub>f</sub>RH5 was produced  
706 by transient co-transfection of HEK293F cells with a plasmid encoding BirA biotin ligase and  
707 a plasmid encoding a modified full-length P<sub>f</sub>RH5. The P<sub>f</sub>RH5 plasmid was based on 'RH5-bio'  
708 (gift from Gavin Wright [Addgene plasmid # 47780;  
709 [http://n2t.net/addgene:47780;RRID:Addgene\\_47780](http://n2t.net/addgene:47780;RRID:Addgene_47780)] (73). RH5-bio was modified prior to  
710 transfection to incorporate a 'C-tag' for subsequent protein purification, as well as a 15 amino  
711 acid deletion at a predicted cleavage site. Probes were freshly prepared for each experiment,  
712 by incubation of monobiotinylated P<sub>f</sub>RH5 with streptavidin-PE (S866, Invitrogen) or  
713 streptavidin-APC (eBioscience, 405207) at an approximately 4:1 molar ratio to facilitate  
714 tetramer generation and subsequently centrifuging to remove aggregates. Following surface  
715 staining, cells were fixed with CytoFix/CytoPerm (554714, BD Biosciences), washed, and  
716 stored at 4°C until acquisition.

717

718 Memory PfrH5-specific IgG<sup>+</sup> B cells identified as live CD19<sup>+</sup>CD21<sup>+</sup>CD27<sup>+</sup>IgG<sup>+</sup>IgM-  
719 PfrH5/APC<sup>+</sup>PfrH5/PE<sup>+</sup> lymphocytes unless otherwise specified (**Supplemental Figure 1**)  
720 and acquired on a Fortessa X20 flow cytometer with FACSDiva8.0 (both BD Biosciences).  
721 Samples were analysed using FlowJo (v10; Treestar). Samples were excluded from analysis  
722 if <100 cells in the parent population.

723

## 724 Standardised ELISAs

725 Standardised ELISAs were used to quantify serum RH5.1-specific IgG1, IgG2, IgG3, IgA,  
726 IgA1, IgA2 and IgM responses in vaccinees. Nunc MaxiSorp™ flat-bottom ELISA plates (44-  
727 2404-21, Invitrogen) were coated overnight with 5µg/mL of RH5.1 protein in PBS. Plates were  
728 washed with washing buffer composed of PBS containing 0.05% TWEEN® 20 (P1379, Sigma-  
729 Aldrich) and blocked with 100µL of Blocker™ Casein in PBS (37582, ThermoFisher Scientific).  
730 After removing blocking buffer, standard curve and internal controls were created in casein  
731 using a pool of high-titre volunteer plasma, specific for each isotype or subclass being tested,  
732 and 50µL of each dilution was added to the plate in duplicate. Test samples were diluted in  
733 casein to a minimum dilution of 1:50 and 50µL was added in triplicate. Plates were incubated  
734 for 2 hours at 37°C and washed in washing buffer. An alkaline phosphatase-conjugated  
735 secondary antibody from Southern Biotech was diluted at the manufacturer's recommend  
736 minimum dilution for ELISA in casein. The antibody used was dependent on the isotype or  
737 subclass being assayed and were as follows: Mouse Anti-Human IgG1 Fc-AP (9054-04),  
738 Mouse Anti-Human IgG2 Fc-AP (9060-04), Mouse Anti-Human IgG3 Hinge-AP (9210-04),  
739 Mouse Anti-Human IgG4 Fc-AP (9200-04), Goat Anti-Human IgA-AP (2050-04), Mouse Anti-  
740 Human IgA1-AP (9130-04), Mouse Anti-Human IgA2-AP (9140-04), Goat Anti-Human IgM-AP  
741 (2020-04). 50µL of the secondary antibody dilution was added to each well of the plate and  
742 incubated for 1 h at 37°C. Plates were developed using PNPP alkaline phosphatase substrate  
743 (N2765, Sigma-Aldrich) for 1-4 h at 37°C. Optical density at 405 nm was measured using an  
744 ELx808 absorbance reader (BioTek) until the internal control reached an OD<sub>405</sub> of 1. The

745 reciprocal of the internal control dilution giving an OD<sub>405</sub> of 1 was used to assign an AU value  
746 of the standard. Gen5 ELISA software v3.04 (BioTek) was used to convert the OD<sub>405</sub> of test  
747 samples into AU values by interpolating from the linear range of the standard curve fitted to a  
748 four-parameter logistics model. Any samples with an OD<sub>405</sub> below the linear range of the  
749 standard curve at the minimum dilution tested were assigned a minimum AU value according  
750 to the lower limit of quantification of the assay.

751

## 752 **Systems serology**

753 The PfRH5 systems serology analyses were performed as previously reported (1). A total of  
754 49 parameters were measured in the assays outlined below: THP-1 phagocytosis, neutrophil  
755 phagocytosis, NK cell activation (3 read-outs), complement deposition, antibody isotype and  
756 subclass (9 read-outs including total IgG avidity), FcR-binding (8 read-outs), C1q binding, and  
757 frequencies of glycan structures (13 read-outs). These assays were performed at  
758 Massachusetts General Hospital (MGH) using plasma samples from the VAC063 trial and  
759 were deemed not human research following review by the MGH Institutional Review Board  
760 (protocol 2012P002452). Additionally, human whole blood and buffy coats were collected at  
761 MGH from healthy donors who did not participate in the VAC063 trial. Use of these internal  
762 samples as sources of uninfected primary neutrophils and NK cells was deemed not human  
763 research by the MGH IRB (protocols 2010 P002121 and 2005 P001218).

764

765 Details of individual assays are described in the Supplemental Materials.

766

## 767 **Single cell RNA sequencing of PfRH5-specific CD19+IgG+ B cells**

768 Similar to as described for the B cell flow cytometry assay, here B cells were enriched (Human  
769 Pan-B cell Enrichment Kit [19554, StemCell]) from cryopreserved PBMC samples from two  
770 weeks after the final vaccination in three DFx vaccinees (50-50---10µg) and four monthly-high  
771 vaccinees (50-50-50µg). These samples were then stained with anti-human CD19-PE-Cy7

772 (557835, BD Biosciences), anti-human IgG-BB515 (564581), FVS780 (565388, BD  
773 Biosciences), as well as two fluorophore-conjugated PfRH5 probes (see flow cytometry  
774 section for more details on probe production (10)). PfRH5-specific B cells identified as live  
775 CD19+IgG+PfRH5/APC+PfRH5/PE+ lymphocytes were single cell sorted on a BD FACS Aria  
776 (BD Biosciences) into Buffer TCL (1031576, Qiagen) with 1% 2-mercaptoethanol. Sorted cells  
777 were snap frozen on dry ice before storage at -80°C until processing.

778

779 mRNA from thawed single B cells was purified with RNAClean XP beads (A63987, Beckam  
780 Coulter) and converted to cDNA using dT<sub>30</sub>VN and TSO oligonucleotides and SMARTScribe  
781 reverse transcriptase (639538, Clontech) with a modified Smart-Seq v4 for Ultra Low Input  
782 RNA protocol (Takara Bio). Both steps were done in the presence of a recombinant RNase  
783 inhibitor (2313B, Takara Bio). cDNA was then amplified with SeqAmp DNA Polymerase  
784 (638509, Clontech).

785

786 HighPrep PCR beads (AC-60050, MagBio) were used to purify cDNA prior to quantification  
787 with Qubit dsDNA HS Assay Kit (Q32854, Life Technologies) and cDNA normalisation.  
788 Sequencing libraries were created using the Nextera Index Kit v2 (FC-131-2001, Illumina) and  
789 the Nextera XT DNA Sample Preparation Kit (FC-131-1096, Illumina). Libraries were then  
790 purified with AMPure XP beads (A63881, Beckman Coulter) and quantified by qPCR with  
791 Library Quantification Kit- Illumina/ ABI Prism (KK4835, KAPA Biosystems). Cells yielding  
792 libraries >1nM by qPCR were normalised and pooled by vaccinee for sequencing on the  
793 HiSeq4000 platform (Illumina) to an average read count of 4,113,948 reads per cell. All cells  
794 were sequenced in a single run. Sequencing was performed on a total of 226 cells from  
795 monthly-high vaccinees (range 37-88 cells) and 228 cells from DFx vaccinees (range 59-88  
796 cells).

797



## 798 Quantification and Statistical Analyses

799

### 800 Computational analysis of systems serology data

801 Multivariate analysis of the systems serology data was performed in R with the following  
802 approach. Features with missing measurements for more than 50% of subjects were removed  
803 from this analysis. Missing values were then imputed using k-nearest neighbors ( $k = 3$ , R  
804 package 'DMwR' v.0.4.1), and all data were mean-centred and variance-scaled ("z-scored").  
805 Univariate differences were assessed with Kruskal-Wallis tests, using the Benjamini-Hochberg  
806 multiple hypothesis correction. Significant differences were then assessed in a pairwise  
807 manner with Mann-Whitney U tests. Partial least-squares discriminant analysis (PLS-DA) was  
808 performed using the 'ropls' (v.1.22.0) and 'systemsseRology' (v1.0) packages of R for model  
809 building and cross-validation/visualization respectively. Significant features were chosen via  
810 the LASSO feature selection algorithm, which was run 100 times on the entire dataset using  
811 the function 'select\_lasso' from the 'systemsseRology' R package ([https://github.com/LoosC/  
812 systemsseRology](https://github.com/LoosC/systemsseRology)). Features chosen in at least 80% of repetitions were used to build PLS-DA  
813 classifiers. PLS-DA model performances were then assessed using a five-fold cross validation  
814 approach and reported cross-validation accuracy is the mean of 10 rounds of 5-fold cross  
815 validation, which includes 100 repeats of feature selection per fold per round. To assess the  
816 importance of selected features, negative control models were built both by permuting group  
817 labels and by selecting random, size-matched features in place of true selected features. 10  
818 rounds of cross-validation with 5 permutation and 5 random-feature trials per round were  
819 performed (again with 100 repeats of feature selection per fold per round for the permutation  
820 trials), and exact  $p$  values were obtained from the tail probability of the generated null  
821 distribution. Correlation networks were built to reveal additional serology features significantly  
822 associated with the selected features. Serology features significantly ( $p < 0.05$ , after a  
823 Benjamini-Hochberg correction) correlated (Spearman  $r_s > |0.7|$ ) via Spearman correlation  
824 were selected as co-correlates. Correlation coefficients were calculated using the 'correlate'

825 function in the 'Corrr' package (v0.4.3), with  $p$  values corrected using 'p.adjust' from the 'stats'  
826 package (v4.0.3). Network visualization was performed using 'ggraph' (v2.0.5) and 'igraph'  
827 (v1.2.6) packages, with manual label and node positioning corrections made in Adobe  
828 Illustrator (v2020) for improved visualization. The gradient color of edges represents  
829 correlation value between the features, represented as nodes. Nodes are colored according  
830 to selected status, with grey nodes as selected features and white nodes as co-correlate  
831 features. An R notebook for the analysis is available.

832

### 833 [Single cell RNA sequencing](#)

834 All scRNA-seq gene expression analysis was performed using the Human Cell Atlas instance  
835 of the Galaxy biocomputing framework (<https://humancellatlas.usegalaxy.eu> (74, 75)) based  
836 on the "Reference-based RNA-seq data analysis" (76) and "Pre-processing of Single-Cell  
837 RNA data" (77, 78) workflow templates. Paired-end FASTQ reads were aligned to the human  
838 genome (hg19) with gene annotations from Ensembl (Homo\_sapiens.GRCh37.75.gtf (79))  
839 using Trimmomatic (80) followed by RNASTar (81). After removing multiply mapped reads, the  
840 number of reads mapped to each gene was quantified with FeatureCounts (82) using a GTF  
841 file groomed with StringTie Merge (83) to annotate genes. Heterogeneity in gene expression  
842 was then explored with either Seurat (84) in R (v4.1.0) – including PCA for downstream  
843 Louvain clustering and UMAP visualisation – or with DESeq2 and Annotate DESeq2 in Galaxy.  
844 Harmony (85) was used to adjust for the possibility of batch effects prior to the clustering/  
845 UMAP analyses. Expression of genes of interest was compared between cluster 4 and other  
846 clusters using Wilcoxon Rank Sum Tests with Bonferroni correction for multiplicity of testing  
847 (individual genes;  $p_{adj}$ ). Enrichment of genes in a plasma cell gene set  
848 ("TARTE\_PLASMA\_CELLS\_VS\_B\_LYMPHOCYTE\_UP" (32) accessed from  
849 <https://www.gsea-msigdb.org/gsea/msigdb>) was likewise compared with a Kruskal-Wallis test  
850 (gene set;  $p$  value). Differentially expressed genes identified with DESeq2 are reported  
851 alongside adjusted  $p$  values ( $p_{adj}$ ) following an FDR correction (Benjamini-Hochberg).

852 Pathway analysis was also performed using Fgsea (fast gene set enrichment analysis;  
853 Korotkevitch *et al.* bioRxiv 060012; doi: <https://doi.org/10.1101/060012>) using either all  
854 transcript counts, or only those with significantly different expression between groups  
855 ( $p_{adj} < 0.05$  following DESeq2). Hallmark and Kegg mSigDB gene sets were used to define  
856 enriched gene sets from previously curated databases. Reproducible Galaxy workflows are  
857 available from the Lead Contact on request.

858

859 BCR CDR3 repertoire analysis was performed with the MiXCR Analyze shotgun pipeline,  
860 designed for clonotype analysis of non-(VDJ)-enriched RNA sequencing data (86, 87). Only  
861 productive rearrangements were considered for downstream analysis. If multiple heavy or light  
862 chain clones were reported for a given cell the clones with the highest read counts were used  
863 for analysis. CDR3 percentage germline mutations were calculated as averages from V-D-J  
864 (heavy chain clones only) or V-J only (heavy and light chain clones). CDR3 length and V gene  
865 usage are direct outputs of MiXCR. Hierarchical clustering of CDR3 amino acid sequences  
866 was performed using Geneious Tree Builder (Alignment type = Global alignment; Genetic  
867 Distance Model: Jukes-Cantor; Tree Build Method: Neighbor-Joining). Dendrograms were  
868 generated in Geneious (showing unrooted tree as rooted; proportional transformation).

869

## 870 [Additional Resources](#)

871 Further information on the relevant clinical trial (NCT02927145) can be found here:

872 <https://clinicaltrials.gov/ct2/show/NCT02927145>.

## 873 Acknowledgments

874 We thank the volunteers and clinical staff for participating in and running the clinical trials  
875 essential for this study, especially Fay Nugent, Yrene Themistocleous, Alison Lawrie, and Ian  
876 Poulton. We also acknowledge technical laboratory support from David Ambrose, Andrew  
877 Worth and Julie Furze, sequencing analysis advice from Jennifer Hillman-Jackson and Björn  
878 Grüning. Finally, assistance with pilot work from Sarah Hamilton, and Marc Lievens, Danielle  
879 Morelle and GSK for participation in the study design and supply of the AS01<sub>B</sub> adjuvant.  
880 C.M.N. was supported by a Sir Henry Wellcome Postdoctoral Fellowship (209200/Z/17/Z).  
881 S.J.D. was supported by a Wellcome Trust Senior Fellowship (106917/Z/15/Z). S.J.D. was  
882 also a Lister Institute Research Prize Fellow and a Jenner Investigator. The ChAd63-MVA trial  
883 (NCT02181088) was supported by funding from the European Union Seventh Framework  
884 Programme (FP7/2007-2013) under the grant agreement for MultiMalVax (no. 305282). The  
885 protein/AS01<sub>B</sub> trial (NCT02927145) was funded by MRC grant MR/K025554/1 and the Office  
886 of Infectious Diseases, Bureau for Global Health, US Agency for International Development  
887 (USAID), under the terms of the Malaria Vaccine Development Program (MVDP) contract AID-  
888 OAA-C-15-00071, for which Leidos is the prime contractor. Both clinical studies were also  
889 supported in part by UK NIHR infrastructure through the NIHR Oxford Biomedical Research  
890 Centre. The Freiburg Galaxy Team at the University of Freiburg (Germany) is funded by the  
891 Collaborative Research Centre 992 Medical Epigenetics (DFG grant SFB 992/1 2012) and the  
892 German Federal Ministry of Education and Research BMBF grant 031 A538A de.NBI-RBC.  
893 The Galaxy server is in part funded by Collaborative Research Centre 992 Medical  
894 Epigenetics (DFG grant SFB 992/1 2012) and German Federal Ministry of Education and  
895 Research (BMBF grants 031 A538A/A538C RBC, 031L0101B/031L0101C de.NBI-epi,  
896 031L0106 de.STAIR (de.NBI)). The opinions expressed herein are those of the authors and  
897 do not necessarily reflect the views of the US Agency for International Development.  
898 GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version

899 of this manuscript for factual accuracy, but the authors are solely responsible for final content  
900 and interpretation.

901

## 902 Author contributions

903 C.M.N. led the study. R.O.P., A.M.M., and S.J.D. were chief, principal, or lead investigators  
904 on the clinical trials. C.M.N., J.R.B, J.K.F., A.R.M., F.L., and S.E.S. performed experiments.  
905 C.M.N, J.R.B., C.D., J.K.F., C. Goh, C. Griffin, A.K., C.L., S.D., M.T., D.A.L., and G.A. analysed  
906 and/or reviewed data. F.L., J.F. and A.R. supported project management and training. R.O.P,  
907 A.M.M, R.A.S., D.C.D., G.A., and S.J.D. contributed reagents, materials and/or analysis tools.  
908 C.M.N. wrote the manuscript.

909

## 910 Declaration of interests

911 S.J.D. is a named inventor on patent applications relating to PfRH5 and/or other malaria  
912 vaccines and immunisation regimens. A.M.M. has an immediate family member who is listed  
913 as an inventor on patents relating to PfRH5 and/or other malaria vaccines and immunisation  
914 regimens. No other authors declare any potential conflicts of interest.

## 915 References

- 916
- 917 1. Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, et al. Reduced blood-stage  
918 malaria growth and immune correlates in humans following RH5 vaccination. *Med (N Y)*.  
919 2021;2(6):701-19 e19.
- 920 2. Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria Vaccines:  
921 Recent Advances and New Horizons. *Cell Host Microbe*. 2018;24(1):43-56.
- 922 3. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity of  
923 standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell*. 2021.
- 924 4. Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and  
925 immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy  
926 of two randomised controlled trials (COV001 and COV002). *Lancet*. 2021;398(10304):981-90.
- 927 5. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose  
928 administration and the influence of the timing of the booster dose on immunogenicity and efficacy  
929 of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet*.  
930 2021;397(10277):881-91.
- 931 6. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary  
932 evaluation of a recombinant circumsporozoite protein vaccine against *Plasmodium falciparum*  
933 malaria. *New England Journal of Medicine*. 1997;336(2):86-91.
- 934 7. Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, et al. Fractional Third  
935 and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria  
936 Parasite Infection and Immunogenicity Study. *J Infect Dis*. 2016;214(5):762-71.
- 937 8. Moon JE, Ockenhouse C, Regules JA, Vekemans J, Lee C, Chuang I, et al. A Phase IIa  
938 Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B  
939 Delayed Fractional Dose Regimens in Malaria-Naive Adults. *J Infect Dis*. 2020;222(10):1681-91.
- 940 9. Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille-Reece U, et al. A delayed fractionated  
941 dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell  
942 responses. *Elife*. 2020;9.
- 943 10. Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doleman SE, Chen Y, Silk SE, et al. Protein/AS01B  
944 vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell  
945 responses than heterologous viral vectors. *Cell Rep Med*. 2021;2(3):100207.
- 946 11. Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, et al. Human vaccination against  
947 RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. *JCI*  
948 *Insight*. 2017;2(21).
- 949 12. Jin J, Tarrant RD, Bolam EJ, Angell-Manning P, Soegaard M, Pattinson DJ, et al. Production,  
950 quality control, stability, and potency of cGMP-produced *Plasmodium falciparum* RH5.1 protein  
951 vaccine expressed in *Drosophila* S2 cells. *NPJ Vaccines*. 2018;3:32.
- 952 13. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, et al. Dissecting Polyclonal  
953 Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. *Cell*. 2015;163(4):988-98.
- 954 14. Chung AW, Alter G. Systems serology: profiling vaccine induced humoral immunity against  
955 HIV. *Retrovirology*. 2017;14(1):57.
- 956 15. Jennewein MF, Abu-Raya B, Jiang Y, Alter G, Marchant A. Transfer of maternal immunity and  
957 programming of the newborn immune system. *Semin Immunopathol*. 2017;39(6):605-13.
- 958 16. Minassian AM, Silk SE, Barrett JR, Nielsen CM. Reduced blood-stage malaria growth and  
959 immune correlates in humans following RH5 vaccination. *Med*. 2021;2:1-19.
- 960 17. Flach H, Rosenbaum M, Duchniewicz M, Kim S, Zhang SL, Cahalan MD, et al. Mzb1 protein  
961 regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells.  
962 *Immunity*. 2010;33(5):723-35.
- 963 18. Rosenbaum M, Andreani V, Kapoor T, Herp S, Flach H, Duchniewicz M, et al. MZB1 is a  
964 GRP94 cochaperone that enables proper immunoglobulin heavy chain biosynthesis upon ER stress.  
965 *Genes Dev*. 2014;28(11):1165-78.

- 966 19. Schiller HB, Mayr CH, Leuschner G, Strunz M, Staab-Weijnitz C, Preisendorfer S, et al. Deep  
967 Proteome Profiling Reveals Common Prevalence of MZB1-Positive Plasma B Cells in Human Lung and  
968 Skin Fibrosis. *Am J Respir Crit Care Med*. 2017;196(10):1298-310.
- 969 20. Andreani V, Ramamoorthy S, Pandey A, Lupar E, Nutt SL, Lammermann T, et al. Cochaperone  
970 Mzb1 is a key effector of Blimp1 in plasma cell differentiation and beta1-integrin function. *Proc Natl*  
971 *Acad Sci U S A*. 2018;115(41):E9630-E9.
- 972 21. Miyagawa-Hayashino A, Yoshifuji H, Kitagori K, Ito S, Oku T, Hirayama Y, et al. Increase of  
973 MZB1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes.  
974 *Arthritis Res Ther*. 2018;20(1):13.
- 975 22. Suzuki K, Vogelzang A, Fagarasan S. MZB1 folding and unfolding the role of IgA. *Proc Natl*  
976 *Acad Sci U S A*. 2019;116(27):13163-5.
- 977 23. Chanukuppa V, Paul D, Taunk K, Chatterjee T, Sharma S, Shirolkar A, et al. Proteomics and  
978 functional study reveal marginal zone B and B1 cell specific protein as a candidate marker of multiple  
979 myeloma. *Int J Oncol*. 2020;57(1):325-37.
- 980 24. Wei H, Wang JY. Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis. *Int*  
981 *J Mol Sci*. 2021;22(5).
- 982 25. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is  
983 essential for the survival of long-lived bone marrow plasma cells. *J Exp Med*. 2004;199(1):91-8.
- 984 26. Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple  
985 Myeloma: Potential Uses of BCMA-Based Immunotherapy. *Front Immunol*. 2018;9:1821.
- 986 27. Lightman SM, Utley A, Lee KP. Survival of Long-Lived Plasma Cells (LLPC): Piecing Together  
987 the Puzzle. *Front Immunol*. 2019;10:965.
- 988 28. Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, et al. Challenges and  
989 Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations. *Front*  
990 *Immunol*. 2019;10:2458.
- 991 29. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G, et al. A coordinated change in  
992 chemokine responsiveness guides plasma cell movements. *J Exp Med*. 2001;194(1):45-56.
- 993 30. Minnich M, Tagoh H, Bonelt P, Axelsson E, Fischer M, Cebolla B, et al. Multifunctional role of  
994 the transcription factor Blimp-1 in coordinating plasma cell differentiation. *Nat Immunol*.  
995 2016;17(3):331-43.
- 996 31. Ellebedy AH, Jackson KJ, Kissick HT, Nakaya HI, Davis CW, Roskin KM, et al. Defining antigen-  
997 specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination.  
998 *Nat Immunol*. 2016;17(10):1226-34.
- 999 32. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J, Jr. Gene expression profiling of plasma cells  
1000 and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. *Blood*.  
1001 2003;102(2):592-600.
- 1002 33. Castro CD, Flajnik MF. Putting J chain back on the map: how might its expression define  
1003 plasma cell development? *J Immunol*. 2014;193(7):3248-55.
- 1004 34. Pae J, Victora GD. B is for 'Big Mac': GCs crave a high-fat diet. *Nat Immunol*. 2020;21(3):249-  
1005 50.
- 1006 35. Weisel FJ, Mullett SJ, Elsner RA, Menk AV, Trivedi N, Luo W, et al. Germinal center B cells  
1007 selectively oxidize fatty acids for energy while conducting minimal glycolysis. *Nat Immunol*.  
1008 2020;21(3):331-42.
- 1009 36. Quiding-Jarbrink M, Lakew M, Nordstrom I, Banchereau J, Butcher E, Holmgren J, et al.  
1010 Human circulating specific antibody-forming cells after systemic and mucosal immunizations:  
1011 differential homing commitments and cell surface differentiation markers. *Eur J Immunol*.  
1012 1995;25(2):322-7.
- 1013 37. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, et al. HLA-DR<sup>high</sup>/CD27<sup>high</sup>  
1014 plasmablasts indicate active disease in patients with systemic lupus erythematosus. *Ann Rheum Dis*.  
1015 2010;69(1):305-8.

- 1016 38. Chaudhury S, Regules JA, Darko CA, Dutta S, Wallqvist A, Waters NC, et al. Delayed fractional  
1017 dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits  
1018 serum opsonophagocytosis. *Sci Rep.* 2017;7(1):7998.
- 1019 39. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector  
1020 functions. *Front Immunol.* 2014;5:520.
- 1021 40. Collins AM, Jackson KJ. A Temporal Model of Human IgE and IgG Antibody Function. *Front*  
1022 *Immunol.* 2013;4:235.
- 1023 41. McCall MBB, Yap XZ, Bousema T. Optimizing RTS,S Vaccination Strategies: Give It Your Best  
1024 Parting Shot. *J Infect Dis.* 2020;222(10):1581-4.
- 1025 42. Alanine DGW, Quinkert D, Kumarasingha R, Mehmood S, Donnellan FR, Minkah NK, et al.  
1026 Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies. *Cell.*  
1027 2019;178(1):216-28 e21.
- 1028 43. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human  
1029 antibodies to pneumococcal capsular polysaccharides. *Infect Immun.* 1999;67(5):2366-70.
- 1030 44. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of  
1031 antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory  
1032 syncytial virus disease. *Nat Med.* 2009;15(1):34-41.
- 1033 45. Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, et al. Antibodies with high avidity  
1034 to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251)  
1035 acquisition in an immunization regimen that mimics the RV-144 Thai trial. *J Virol.* 2013;87(3):1708-  
1036 19.
- 1037 46. Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective  
1038 immunity towards SARS-CoV-2. *Int J Infect Dis.* 2021;106:61-4.
- 1039 47. Gaudinski MR, Berkowitz NM, Idris AH, Coates EE, Holman LA, Mendoza F, et al. A  
1040 Monoclonal Antibody for Malaria Prevention. *N Engl J Med.* 2021.
- 1041 48. Kisalu NK, Pereira LD, Ernste K, Flores-Garcia Y, Idris AH, Asokan M, et al. Enhancing  
1042 durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. *JCI*  
1043 *Insight.* 2021;6(3).
- 1044 49. Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, et al. Anti-HA Glycoforms  
1045 Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. *Cell.* 2015;162(1):160-9.
- 1046 50. Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, et al. Innate transcriptional  
1047 effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.  
1048 *Blood Adv.* 2017;1(25):2329-42.
- 1049 51. Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V, et al. Antibody  
1050 avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. *NPJ Vaccines.*  
1051 2021;6(1):78.
- 1052 52. King HW, Orban N, Riches JC, Clear AJ, Warnes G, Teichmann SA, et al. Single-cell analysis of  
1053 human B cell maturation predicts how antibody class switching shapes selection dynamics. *Sci*  
1054 *Immunol.* 2021;6(56).
- 1055 53. O'Connor BP, Cascalho M, Noelle RJ. Short-lived and long-lived bone marrow plasma cells  
1056 are derived from a novel precursor population. *J Exp Med.* 2002;195(6):737-45.
- 1057 54. Weisel FJ, Zuccarino-Catania GV, Chikina M, Shlomchik MJ. A Temporal Switch in the  
1058 Germinal Center Determines Differential Output of Memory B and Plasma Cells. *Immunity.*  
1059 2016;44(1):116-30.
- 1060 55. Manakkat Vijay GK, Singh H. Cell fate dynamics and genomic programming of plasma cell  
1061 precursors. *Immunol Rev.* 2021;303(1):62-71.
- 1062 56. Cirelli KM, Carnathan DG, Nogal B, Martin JT, Rodriguez OL, Upadhyay AA, et al. Slow  
1063 Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via  
1064 Modulation of Immunodominance. *Cell.* 2019;177(5):1153-71 e28.
- 1065 57. Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2 mRNA  
1066 vaccines induce persistent human germinal centre responses. *Nature.* 2021;596(7870):109-13.



- 1067 58. Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, et al.  
1068 Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope  
1069 Trimer Immunization Using Optimized Approaches. *Immunity*. 2017;46(6):1073-88 e6.
- 1070 59. Mei HE, Wirries I, Frolich D, Brisslert M, Giesecke C, Grun JR, et al. A unique population of  
1071 IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. *Blood*.  
1072 2015;125(11):1739-48.
- 1073 60. Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoret IV, et al. Long-Lived  
1074 Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.  
1075 *Immunity*. 2015;43(1):132-45.
- 1076 61. Arumugakani G, Stephenson SJ, Newton DJ, Rawstron A, Emery P, Doody GM, et al. Early  
1077 Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell  
1078 Transition. *J Immunol*. 2017;198(12):4618-28.
- 1079 62. Garimalla S, Nguyen DC, Halliley JL, Tipton C, Rosenberg AF, Fucile CF, et al. Differential  
1080 transcriptome and development of human peripheral plasma cell subsets. *JCI Insight*. 2019;4(9).
- 1081 63. Lau D, Lan LY, Andrews SF, Henry C, Rojas KT, Neu KE, et al. Low CD21 expression defines a  
1082 population of recent germinal center graduates primed for plasma cell differentiation. *Sci Immunol*.  
1083 2017;2(7).
- 1084 64. Vijay GKM, Singh H. Cell fate dynamics and genomic programming of plasma cell  
1085 precursors. *Immunological Reviews*. 2021;303:62-71.
- 1086 65. Chevrier S, Emslie D, Shi W, Kratina T, Wellard C, Karnowski A, et al. The BTB-ZF transcription  
1087 factor Zbtb20 is driven by Irf4 to promote plasma cell differentiation and longevity. *J Exp Med*.  
1088 2014;211(5):827-40.
- 1089 66. Turner JS, Zhou JQ, Han J, Schmitz AJ, Rizk AA, Alsoussi WB, et al. Human germinal centres  
1090 engage memory and naive B cells after influenza vaccination. *Nature*. 2020;586(7827):127-32.
- 1091 67. Laidlaw BJ, Ellebedy A. The germinal centre B cell response to SARS-CoV-2. *Nat Rev Immunol*.  
1092 2021.
- 1093 68. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, et al. FcγRIIb  
1094 controls bone marrow plasma cell persistence and apoptosis. *Nat Immunol*. 2007;8(4):419-29.
- 1095 69. Thompson HA, Hogan AB, Walker PGT, White MT, Cunningham AJ, Ockenhouse CF, et al.  
1096 Modelling the roles of antibody titre and avidity in protection from *Plasmodium falciparum* malaria  
1097 infection following RTS,S/AS01 vaccination. *Vaccine*. 2020;38(47):7498-507.
- 1098 70. Das J, Fallon JK, Yu TC, Michell A, Suscovich TJ, Linde C, et al. Delayed fractional dosing with  
1099 RTS,S/AS01 improves humoral immunity to malaria via a balance of polyfunctional NANP6- and Pf16-  
1100 specific antibodies. *Med*. 2021;2(11):1269-86.e9.
- 1101 71. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al. Safety and  
1102 efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-  
1103 immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. *Lancet Infect  
1104 Dis*. 2011;11(10):741-9.
- 1105 72. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and  
1106 plasma cells. *Immunol Rev*. 2012;247(1):52-63.
- 1107 73. Crosnier C, Wanaguru M, McDade B, Osier FH, Marsh K, Rayner JC, et al. A library of  
1108 functional recombinant cell-surface and secreted *P. falciparum* merozoite proteins. *Mol Cell  
1109 Proteomics*. 2013;12(12):3976-86.
- 1110 74. Jalili V, Afgan E, Gu Q, Clements D, Blankenberg D, Goecks J, et al. The Galaxy platform for  
1111 accessible, reproducible and collaborative biomedical analyses: 2020 update. *Nucleic Acids Res*.  
1112 2020;48(W1):W395-W402.
- 1113 75. Moreno P, Huang N, Manning JR, Mohammed S, Solovyev A, Polanski K, et al. User-friendly,  
1114 scalable tools and workflows for single-cell RNA-seq analysis. *Nat Methods*. 2021;18(4):327-8.
- 1115 76. Batut B, Freeberg M, Heydarian M, Erxleben A, Videm P, Blank C, et al. Reference-based  
1116 RNA-Seq data analysis 2021 [Available from: [https://training.galaxyproject.org/training-  
1117 material/topics/transcriptomics/tutorials/ref-based/tutorial.html](https://training.galaxyproject.org/training-material/topics/transcriptomics/tutorials/ref-based/tutorial.html)].

- 1118 77. Tekman M, Batut B, Ostrovsky A, Antoniewski C, Clements D, Ramirez F, et al. A single-cell  
1119 RNA-sequencing training and analysis suite using the Galaxy framework. *Gigascience*. 2020;9(10).  
1120 78. Bacon W. Filter, Plot and Explore Single-cell RNA-seq Data 2021 [Available from:  
1121 [https://training.galaxyproject.org/training-material/topics/transcriptomics/tutorials/scrna-seq-](https://training.galaxyproject.org/training-material/topics/transcriptomics/tutorials/scrna-seq-basic-pipeline/tutorial.html)  
1122 [basic-pipeline/tutorial.html](https://training.galaxyproject.org/training-material/topics/transcriptomics/tutorials/scrna-seq-basic-pipeline/tutorial.html).  
1123 79. Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, et al. Ensembl 2019.  
1124 *Nucleic Acids Res*. 2019;47(D1):D745-D51.  
1125 80. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data.  
1126 *Bioinformatics*. 2014;30(15):2114-20.  
1127 81. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal  
1128 RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21.  
1129 82. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning  
1130 sequence reads to genomic features. *Bioinformatics*. 2014;30(7):923-30.  
1131 83. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables  
1132 improved reconstruction of a transcriptome from RNA-seq reads. *Nat Biotechnol*. 2015;33(3):290-5.  
1133 84. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, et al. Integrated  
1134 analysis of multimodal single-cell data. *Cell*. 2021;184(13):3573-87 e29.  
1135 85. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and  
1136 accurate integration of single-cell data with Harmony. *Nat Methods*. 2019;16(12):1289-96.  
1137 86. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, et al. MiXCR:  
1138 software for comprehensive adaptive immunity profiling. *Nat Methods*. 2015;12(5):380-1.  
1139 87. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT,  
1140 the international ImMunoGeneTics information system. *Nucleic Acids Res*. 2009;37(Database  
1141 issue):D1006-12.  
1142